Skip to main content

Advertisement

Table 2 PSA and ALP change

From: A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

  PSA before switch from GnRH antagonist to agonist PSA after switch from GnRH antagonist to agonist p value
PSA (ng/ml) 2.7 ± 8.8 2.0 ± 5.1 0.286
  ALP before switch from GnRH antagonist to agonist ALP after switch from GnRH antagonist to agonist  
ALP (IU/L) 378 ± 545 387 ± 772 0.905
  1. Abbreviations PSA prostate specific antigene, ALP alkaline phosphatase, GnRH gonadotropin releasing hormone